🇺🇸United States·April 16, 2026·daily

US Earnings Financial Results SEC Filings — April 16, 2026

Across 32 filings primarily covering FY2025 10-Ks and Q1 2026 10-Qs, sentiment is overwhelmingly mixed (25/32), with microcap/development-stage firms (e.g., SEATech, JOCOM, Catalyst Crew) showing narrowed losses via expense cuts (avg ~70% improvement in 8 cases) but persistent zero revenue and going concern risks, while larger caps like PepsiCo (+8.6% revenue YoY), Fastenal (+12.4%), and Travelers (+333% net income) drove positive trends. Portfolio-level, revenue grew in 12/32 (avg +20% YoY where positive), but declined in 14 (avg -40%), with gross margins compressing in 10/32 (avg -200bps, e.g., Lakeland -820bps). Acquisitions/share issuances boosted assets in 15 firms (avg +100% YoY), but cash burn persists in 20+, offset by financing. Capital allocation leans toward buybacks/dividends in stables (Travelers $1.8B buyback, Fastenal dividend +12%), signaling conviction, while microcaps dilute via issuances. Key implication: Opportunities in turnaround microcaps narrowing losses and established consumer/insurance names, but watch margin pressures and working capital deficits amid 2026 economic uncertainty.

32 high priority32 total filings

🇺🇸United States·April 15, 2026·daily

US Earnings Financial Results SEC Filings — April 15, 2026

Across 50 US SEC 10-K filings for FY2025 (period ending ~Dec 31, 2025), small-cap and micro-cap companies dominate with mixed sentiment (28/50 mixed, 10 negative), reflecting persistent operating losses amid revenue volatility: 22 companies saw revenue declines (avg -35% YoY, e.g., Polar Power -55%, Cenntro -42%), while 12 posted growth (avg +85% YoY, outliers Gloo Holdings +308%, Vivakor segment +87%). Net losses widened in 60% of filers (avg +50% YoY magnitude), driven by R&D/SG&A spikes and impairments, though 8 achieved profitability swings via one-offs (e.g., Oncotelic +$249M from investment fair value). Balance sheets improved via $1B+ aggregate financing (equity/debt), boosting cash/assets in 65% but deepening dilutions/shareholder deficits elsewhere; cash burn worsened in 70% (avg +40% YoY operating use). SPACs (e.g., Horizon Space, Constellation) faced heavy redemptions (avg 90% trust erosion), signaling de-SPAC fatigue. Biotech/pharma (12/50) showed R&D escalation (+100% avg) with commercialization catalysts, while energy/mining had modest production gains. Implications: Favor turnaround outliers with revenue ramps and monitor liquidity risks; portfolio tilt to revenue growers like Citi Trends amid broad weakness.

50 high priority50 total filings

🇺🇸United States·April 14, 2026·daily

US Earnings Financial Results SEC Filings — April 14, 2026

Across 45 SEC filings in the Financial Results & Earnings stream (mostly 10-Q/10-K from small-cap US companies), overarching themes include widespread revenue declines (17/45 companies reported YoY drops averaging -40%, e.g., SemiLEDs -90%, Greystone -76%) and net loss expansions (25/45 widened losses YoY, avg +50%), offset by financing-driven cash boosts in 30+ cases and explosive growth outliers like BITMINE (+390% rev) and ABQQ (+236%). Mixed sentiment prevails (32/45), with SPACs (8 filings) stable via trust income (e.g., Legato IV +$686k net income from investments), while impairments (Saga $20M goodwill, Heritage $118M intangibles) and related-party reliance signal distress. Period trends show QoQ cash improvements in 20 companies (avg +50%) but margin compression (-150bps avg in 12 reporters) and dilution via share issuances (e.g., BITMINE shares doubled). No broad insider trading patterns, but capital allocation leans conservative (dividends cut in Saga -37.5%, Immersion declared $1.5M). Market implications: High volatility in microcaps, alpha in growth outliers amid sector rotation from cyclicals; portfolio caution on trade policy risks (Northann) and going concerns (Greystone, Go Go Buyers).

45 high priority45 total filings

🇺🇸United States·April 13, 2026·daily

US Earnings Financial Results SEC Filings — April 13, 2026

Across 23 filings, sentiment is predominantly mixed (17/23), reflecting resilient revenue growth in select manufacturers and distributors (e.g., Arts-Way +29% YoY sales, EACO +17.7%) offset by widespread declines in tech, biotech, and consumer sectors (avg revenue drop ~15% YoY in 10 companies including Kopin -21.9%, Biomerica -21.6% 9M). Margin compression is a portfolio-level trend, affecting 9/23 companies with average -150 bps YoY (e.g., Digital Ally to 10% from 23%, Wetouch 31.8% from 32.2%), driven by cost pressures and crypto losses (Pineapple -$23M FV loss). Balance sheets show bifurcation: 8 companies strengthened via financing/dilution (e.g., Pineapple assets x9 to $48.9M, CONX equity positive $55M), while 7 saw cash/inventory deterioration amid operating losses. Net losses narrowed in 10 firms (avg improvement ~30% YoY), but dilution is rampant (12/23 with shares up >10x in cases like Edgemode 7,679% increase). No dominant insider patterns noted, but customer concentration (Wetouch top customers, Elite 100% FedEx) and China risks (Wetouch, others) emerge as systemic vulnerabilities. Q4/Q1 improvements signal potential inflection (New Fortress Q4 rev +19% QoQ), positioning nimble operators for recovery amid economic volatility.

23 high priority23 total filings

🇺🇸United States·April 10, 2026·daily

US Earnings Financial Results SEC Filings — April 10, 2026

Across 22 filings in the Financial Results & Earnings stream, sentiment is predominantly mixed (15/22), with negative tones in retail (Childrens Place -12.8% sales YoY, FGI -1% rev), media (Cumulus -10.3% rev), and digital assets (GD Culture -96.3% cash QoQ), offset by growth outliers like Simulations Plus (+8.3% Q rev YoY, +47.5% NI) and ASP Isotopes (+475% rev). Period-over-period trends show revenue declines averaging -10% YoY in 12/22 companies, but net losses narrowing in 14/22 via cost cuts (e.g., EvoAir op ex -65%, Brownie's working capital +240%), alongside persistent cash burn (16/22 declining cash positions) and equity dilutions (e.g., Balance Labs shares +100%). Capital allocation leans toward financing inflows and equity issuances over dividends/buybacks, with no splits noted; operational metrics highlight R&D surges in biotech/pharma (Quince +90%, Scilex +115%, Stimcell +7316% Q). Portfolio-level implications include sector rotation from consumer/retail to niche tech/services, with alpha in loss-narrowing turnarounds amid high materiality (avg 8/10). No explicit forward-looking guidance or insider trades reported, but trial successes (Scilex SP-102 Phase 3 met endpoints) signal catalysts; watch for cash sustainability in microcaps.

22 high priority22 total filings

🇺🇸United States·April 09, 2026·daily

US Earnings Financial Results SEC Filings — April 09, 2026

Across 24 filings in the Financial Results & Earnings stream, overarching themes reveal a bifurcated market with 14/24 companies reporting YoY revenue declines averaging -12.5% (e.g., Beyond Meat -15.6%, KB Home -22.6%, Lennar -13.3%), driven by housing weakness and consumer pullback, while 10 showed growth averaging +18% (e.g., Healthy Extracts +45%, WD-40 +10.7%, Worthington Enterprises +24.4%). Margin compression affected 9/24 firms (avg -250 bps, e.g., Simply Good Foods impairment), but loss narrowing was common in 12 cases (e.g., Resources Connection net loss -78% YoY, BlackBerry swing to profit). Capital allocation leaned defensive with buybacks/dividends in homebuilders (KB Home $50M repurchases, Lennar $270M), but cash burn rose in 8 microcaps. Homebuilding sector dragged portfolios (revenue -18% avg), contrasting resilient industrials (Worthington +20% sales). SPACs face redemption risks (IX Acquisition trust -52%). Implications: Trim housing exposure, seek turnaround alpha in mixed-sentiment small caps with improving losses.

24 high priority24 total filings

🇺🇸United States·April 08, 2026·daily

US Earnings Financial Results SEC Filings — April 08, 2026

Across 26 filings in the Financial Results & Earnings stream, results are predominantly mixed (17/26), with revenue growth in 12 companies averaging +40% YoY (outliers: Applied Digital +139%, Pure Cycle +47%) offset by sharp declines in 10 others (avg -40% YoY, e.g., Nurix -66%, Aehr -44%). Margin compression is widespread (8/26 companies, avg -150 bps), driven by rising opex/R&D, while net losses widened in 14 firms amid impairments (e.g., Beasley $225M FCC licenses) and cash burn (15/26 cash declines, avg -50%). Positive net income in 6 companies (e.g., Grown Rogue turnaround to $3.2M profit, Jabil +91% YoY) contrasts small-cap struggles, with biotech/pharma and media hit hardest. Capital allocation favors buybacks/dividends in performers (e.g., Pure Cycle repurchases, PriceSmart dividends up), but equity issuances dilute in cash-strapped firms (17/26). Portfolio implication: Rotate into revenue growers like Jabil/Applied Digital; avoid cash-deficient microcaps. Forward risks from low cash (SmartKem $374k) and SPAC deadlines signal near-term catalysts.

26 high priority26 total filings

🇺🇸United States·April 07, 2026·daily

US Earnings Financial Results SEC Filings — April 07, 2026

Across 17 filings, results reveal a bifurcated market with resilient services and financial firms (e.g., Cintas +8.9% YoY revenue, Jefferies +16.1%) offsetting declines in manufacturing/tech (Greenbrier -23% YoY, Cambium -21.8%) and biotechs (Jaguar Health losses widening 37.6% YoY), yielding aggregate revenue growth near flat but with margin volatility (improvements in Cambium +160 bps gross margin, compressions in UniFirst op income -16.7%). Capital allocation leans shareholder-friendly via buybacks (Cintas $933M YTD, UniFirst $33M H1) and dividends (Greenbrier $0.64/share, Phoenix $0.21/share), though cash burn persists in early-stage firms (Cell Source going concern doubt, Thunder Power cash to $10K). SPACs show IPO strength (APEX trust $112M), while education peers struggle (Skillsoft flat revenue, Phoenix net income -58%). Forward-looking catalysts cluster in biotech milestones (Cell Source Phase 2 by 2028), with no major guidance changes but elevated risks from impairments (Cambium $25.5M, Skillsoft 6.2% of rev). Portfolio implication: Favor services/consumer outperformers amid cyclical weakness, monitor cash flows for 9 mixed-sentiment names.

17 high priority17 total filings

🇺🇸United States·April 06, 2026·daily

US Earnings Financial Results SEC Filings — April 06, 2026

Across the 8 filings in the Financial Results & Earnings stream, small-cap and micro-cap companies predominantly reported mixed results with revenue growth in standout cases like SolarMax Technology (+296% YoY to $90.982M) and iQSTEL (+11.9% YoY to $316.9M), but widespread margin compression (e.g., SolarMax gross margin -550 bps to 4.6%, iQSTEL Q4 gross margin +72 bps but overall flat), net losses, and cash burn (e.g., STRATEGIC ACQUISITIONS -98% cash to $508, Nutra -90.1% to $3,603). Period-over-period trends show 4/8 companies with YoY revenue growth averaging +82% in winners, but 5/8 with widening or persistent net losses and deteriorating equity positions (e.g., Elvictor swung to -$175k loss, Neolara full asset impairment). Capital allocation leaned toward equity issuances and dividends (iQSTEL stock dividend $500k), with limited buybacks; no major M&A but forward-looking catalysts like Elvictor's nine Q1 2026 crew contracts signal potential turnarounds. Portfolio-level patterns indicate sector-agnostic cash constraints and operational volatility in finance/telecom/solar, implying high-beta opportunities amid Nasdaq compliance risks (SolarMax). Overall materiality skews high (avg 7.4/10), favoring selective longs on growth outliers while shorting cash burners.

8 high priority8 total filings

🇺🇸United States·April 03, 2026·daily

US Earnings Financial Results SEC Filings — April 03, 2026

Across 12 US SEC filings in the Financial Results & Earnings stream, results reveal a bifurcated landscape with robust revenue growth in defense (Karman +36.6% YoY) and professional services (RCM +14.7% YoY, Concentrix +5.4% YoY, Ooma +7% YoY) offsetting sharp declines in lending/BDCs (TCW Direct -44% YoY, TCW VII -35.1% YoY), microcaps (Totaligent -99.5% YoY, Token -85% YoY), and others (POWERDYNE -7.2% YoY). Margin trends are mixed, with compression in 7/12 companies (e.g., Karman -2.9 pts, Concentrix operating -30% YoY) but improvements in adjusted EBITDA for Karman (+37%), Ooma (+46%), and RCM (+19%). Net losses narrowed in loss-making firms like GOOD GAMING (-75.5%), but cash burn persists in 8/12, with liabilities rising in 6/12 amid dilution and debt increases. Capital allocation shows shareholder focus via buybacks (RCM 114k shares, Concentrix 1k shares) and dividends (Concentrix $23M), signaling conviction in outperformers. Portfolio-level pattern: small-cap deterioration (8/12 revenue down avg -50% YoY) vs mid-cap resilience, implying rotation opportunities from distressed names to growth segments like defense/services. No insider activity or explicit guidance noted, but improving debt ratios (Karman 1.52 from 2.25) and backlog growth flag early recovery signals.

12 high priority12 total filings

🇺🇸United States·April 02, 2026·daily

US Earnings Financial Results SEC Filings — April 02, 2026

Across 19 US SEC filings for Q1/FY2025-2026 financial results, results are predominantly mixed (17/19), with revenue growth in 10 companies averaging +22% YoY (led by Navan +31%, Regional Health +190%, DYNA +26%), but declines in 7 averaging -20% YoY (Lindsay -16%, Lovesac other -37%); margins compressed in 7 firms by avg -150bps (Lovesac -210bps, Caleres -190bps, IRIDEX -460bps). Net income swings to profit in 5 (DYNA from -$8.5M to +$3.8M, Regional Health from -$3.2M to +$3.4M), while losses narrowed in 4 but widened in others; operating cash flow improved in 8/15 reported (FactSet +28%, Acuity +20%). Capital allocation favors buybacks ($303M FactSet, $103M Acuity, $80M TD SYNNEX, $56M Lindsay), signaling management conviction amid $1B+ total returns, though cash piles declined QoQ in 10/16 (TD SYNNEX -36%, Acuity -36%). Microcaps face acute risks (Algorhythm going concern, Vitaspring $3.5M deficit), SPACs (Iron Horse, Starry Sea) build trust accounts post-IPO, and medtech/retail show segment shifts (ChargePoint subscriptions +13% mix). Portfolio implication: Favor buyback-heavy mid/large caps (TD SYNNEX, FactSet) for stability, avoid cash-burn shells (Byrn, Vitaspring); sector rotation to distribution/mining growth.

19 high priority19 total filings

🇺🇸United States·March 31, 2026·daily

US Earnings Financial Results SEC Filings — March 31, 2026

Across 50 10-K filings for FY2025 (ended Dec 31, 2025), mixed sentiment dominates with 14/50 explicitly mixed, reflecting turnarounds in select operating companies (e.g., TruBridge net income from -$21M to +$4M, HireQuest +72% net income) amid widespread losses in biotechs/pharma (avg loss expansion +100% YoY in Athira, Sharps, OS Therapies). Revenue trends show resilience in retail (Ross Stores +8% YoY to $22.8B, FitLife +26%) but declines in resources (CKX Lands -45%, SD Soy -9%) and flatlines in tech/services (KORE 0%, TruBridge +1%); operational cash flow improved in 6/15 detailed cos (e.g., Ross +28% to $3B). CMBS trusts (16/50) uniformly neutral with recurring master servicer transitions to Trimont LLC effective Mar 1, 2025, signaling standardization but no delinquencies flagged. SPACs/funds (10/50) hold robust trust assets (e.g., Berto $309M, Invest Green $173M) with low materiality risks pre-combination. Biotech cash burn persists (OS Therapies cash -95% to $270k) offset by financings (Athira PIPE $82M net); capital allocation favors equity raises over dividends/buybacks. Portfolio implication: Favor retail turnaround plays, monitor CMBS servicer shifts for liquidity hints, avoid high-burn biotechs without catalysts.

50 high priority50 total filings

🇺🇸United States·March 30, 2026·daily

US Earnings Financial Results SEC Filings — March 30, 2026

Across 50 10-K and 10-Q filings from March 30, 2026, primarily small-cap biotechs, SPACs, crypto/AI firms, and financial trusts, sentiment is mixed (70% of filings), with 18 companies narrowing net losses YoY (avg improvement 40%, e.g., OneMedNet -72%, ImmuCell -52%) amid revenue volatility: 14 firms grew revenue (avg +95% YoY, outlier OneMedNet +111%), 13 declined (avg -18%, e.g., Soluna -22%, Origin -40%). Biotechs (12 filings) show R&D cuts in 6 but persistent cash burn (avg op cash use +15%), while SPACs (12) hold trust assets ($10B+ aggregate) but report deficits and no combinations. Crypto firms (5) post impairments ($40M+) offset by financing ($150M+ inflows). Capital allocation leans to financing raises ($1B+ aggregate) over dividends/buybacks; no insider trades noted, but 8 firms flag going concerns. Portfolio implications: Selective opportunities in turnarounds like Galaxy Gaming (profitability flip), risks in high-burn biotechs and pre-IPO SPACs; sector rotation toward profitable niches like banks (GBank NI +12%).

50 high priority50 total filings

🇺🇸United States·March 27, 2026·daily

US Earnings Financial Results SEC Filings — March 27, 2026

Across 50 10-K filings for FY ended Dec 31, 2025, a stark divide emerges: 30+ ABS trusts (Ally Auto, Exeter Auto, Navient/SLM Student Loan) confirm full servicing compliance with neutral sentiment and no material issues or metrics, signaling stability in securitized auto/student loan markets. Operating companies (20 filings) reveal volatile growth, with digital asset firms (BitGo +424% YoY revenue to $16.2B, FG Nexus +210% to $2.4M, American Bitcoin +159% to $185M) driving top-line surges but massive net losses from unrealized digital asset impairments (e.g., BitGo -$14.8M vs +$156K prior). SPACs/blank checks (OTG, Republic Digital, Galata II, Launch Two) hold steady trusts yielding interest income (e.g., Launch Two net income +302% YoY to $8.9M), while biotech/tech (Luminar -12% rev, Cyngn -40%, Phunware -20%) face revenue declines and cash burns amid narrowing losses in some (Instil Bio -4% loss improvement, Werewolf -14%). Portfolio trends show average revenue growth +100% YoY in crypto-exposed names but -15% in traditional tech/biotech; cash positions deteriorated in 12/20 operating cos (avg -40% YoY), flagging liquidity risks. No insider trading patterns or M&A noted; steady dividends rare (United Guardian $0.60/share). Implications: Favor crypto growth plays for rebound potential, avoid bleeding tech, monitor trusts for any compliance cracks.

50 high priority50 total filings

🇺🇸United States·March 25, 2026·daily

US Earnings Financial Results SEC Filings — March 25, 2026

Across 50 SEC filings for Q4 2025/FY2025 financial results, mixed sentiment dominates (35/50 filings), with tech/software firms like UiPath (+13% YoY revenue to $1.61B, profitability turnaround) and Pure Storage (+16% to $3.66B) showing revenue growth averaging 17% YoY but flat/declining margins due to opex rises (e.g., R&D +20% at Pure). SPACs (15+ filings) generated net income primarily from trust interest (e.g., Range Capital $4.0M), though redemptions depleted trusts (e.g., Concord 99.6% drop). Biotechs/pharma (10+) faced revenue cliffs (e.g., KIORA $0 vs $16M) and R&D-driven loss widening (avg +50% opex), narrowing losses in oil/gas (CoJax -31%) and select industrials. Portfolio trends: 12/20 operating cos with >10% revenue growth but 8/12 margin compression (-100bps avg); cash burn persists in 70% small caps. Critical implications: Favor tech profitability inflection (UiPath, Braze cash flow double), monitor SPAC liquidations post-redemptions, avoid biotech cash drains without catalysts. Capital allocation leans conservative (e.g., Chewy FCF +24% to $562M), with M&A sparse but accretive (Securetech AI UltraProd).

50 high priority50 total filings

🇺🇸United States·March 24, 2026·daily

US Earnings Financial Results SEC Filings — March 24, 2026

Across 50 filings dated March 24, 2026, primarily FY2025 10-Ks, sentiment is predominantly mixed (24/50) or neutral (18/50), with operating companies showing divergent trends: explosive revenue growth in solar (FTC Solar +110.5% YoY) and AI/hardware (Blaize +2,387% YoY) contrasted by widening net losses in biotechs (e.g., COMPASS +85.6%, Fractyl +105%, Neurogene +20.2%) and sharp declines in energy trusts (VOC -37% income, MV Oil -39%). Retail outliers like GameStop delivered +218.7% net income surge despite -5.1% sales drop via margin expansion (+7.4 pts to 33%), while 25+ ABS/mortgage trusts reported routine Reg AB compliance with no material issues, signaling stable structured finance servicing. Portfolio-level trends reveal biotech cash burn averaging +30% YoY (e.g., Achieve +37%, Neurogene +9.4%), energy reserve/production declines (4-11% YoY), and modest infra growth (Core & Main +2.8% sales). Capital allocation leans toward financing inflows for cash preservation (e.g., FTC +$40.4M), but no broad insider patterns noted; implications favor selective longs in margin improvers amid biotech/energy caution, with ABS neutrality supporting fixed-income stability.

50 high priority50 total filings

🇺🇸United States·March 23, 2026·daily

US Earnings Financial Results SEC Filings — March 23, 2026

Across 50 US SEC filings for FY2025 (ended Dec 31, 2025), sentiment is predominantly mixed (28/50), with neutral ABS trusts (12/50) and negative outliers in consumer/hospitality sectors; revenue trends show sharp declines in consumer goods (avg -30% YoY for Aterian, Solo Brands) offset by growth in mining/biotech (e.g., Idaho Strategic +64.6% YoY, Arbutus +128% YoY). Net losses widened in 18 companies (avg +45% YoY in biotechs like Cabaletta, Surrozen), but narrowed in 12 (e.g., Xilio -40%, Sutro -16%); cash positions improved in 15 firms via financing/IPOs, but burned in biotech heavy-hitters. SPACs (Cartesian, SilverBox, Bold Eagle, TGE) reported strong trust interest income (+300-400% YoY) amid negative equity, signaling de-SPAC catalysts. Capital allocation leaned toward debt reduction (Core Labs -13% net debt, Ultralife -12%) over dividends/buybacks; insider activity limited to 10b5-1 selling plans (Avalo, Pyxis) indicating caution. Portfolio-level: Biotech R&D surges (+30-180% YoY) drive losses but fuel pipelines; consumer margin resilience amid sales drops offers turnaround potential; ABS compliance uniform/neutral implies stable securitizations.

50 high priority50 total filings

🇺🇸United States·March 20, 2026·daily

US Earnings Financial Results SEC Filings — March 20, 2026

Across 50 10-K and 10-Q filings from March 20, 2026, primarily FY2025 results, a dominant mixed sentiment prevails with 70% of named companies showing revenue growth averaging 40% YoY in high-growth sectors like aerospace (Firefly +163%), tech (Snowflake +29%, Aeva +99%), and retail (Dollar General +5.2%, Victoria's Secret +5%) but persistent net losses widening in 60% of cases due to high opEx/R&D and impairments. SPACs (e.g., Pelican, Bluerock, Jackson) represent ~20% of filings, holding intact trust accounts with interest income driving modest profits amid pre-merger deficits. BDC/investment vehicles (11 filings) expanded assets/portfolios 50-80% YoY with investment income up 50-110%, though yields compressed 100bps to 9.1% on average, signaling rate sensitivity. ABS servicing compliance in 15+ unknown filings remains routine/neutral with no deficiencies, focusing on standard timeframes (2-90 days). Capital allocation leans toward financing inflows ($100M+ in Aeva, Firefly) over dividends/buybacks, with outliers like AutoZone's $742M buybacks. Portfolio-level trends highlight growth resilience but profitability challenges, implying near-term catalysts from guidance-embedded EBITDA targets (Wellgistics to 2026) and product launches (Milestone PSVT in 2026).

50 high priority50 total filings

🇺🇸United States·March 19, 2026·daily

US Earnings Financial Results SEC Filings — March 19, 2026

Across 50 filings dominated by neutral ABS servicing compliance disclosures (30+ filings, materiality 3-5/10), key financial reporters show mixed FY2025/Q2 FY2026 results with standout revenue accelerations in tech/memory (Micron +196% YoY Q2 rev to $23.9B) and retail (Ollie's +16.6% sales to $2.65B), offset by declines in health services (DarioHealth -17% rev) and hospitality SSS (ONE Group -3.7%). Aggregate trends reveal 12/20 high-materiality firms with revenue growth averaging +35% YoY (led by Rubrik +48%, Tigo Energy +91.7%), but margins mixed with expansions in 6 (e.g., Micron gross to $17.8B) vs compressions in 7 (avg -150bps where noted); net losses narrowed in 8 biotechs/small caps (e.g., Mustang Bio -88% YoY). Cash positions strengthened in 10 firms (avg +40% YoY, e.g., FedEx to $8B), but deteriorated in 7 (e.g., Lithium Americas liabilities +900%). SPACs (Artius II, Rice) standard pre-deal with trust growth but deficits. No widespread insider activity reported; capital allocation leans reinvestment over returns amid growth focus. Implications: Bullish tech/retail momentum, biotech turnaround watch, ABS stability signal.

50 high priority50 total filings

🇺🇸United States·March 18, 2026·daily

US Earnings Financial Results SEC Filings — March 18, 2026

Across 50 10-K and 10-Q filings for FY2025 (mostly ended Dec 31, 2025, filed Mar 18, 2026), dominant mixed sentiment prevails in 70% of detailed reports, with revenue growth in 18/25 quantifiable companies averaging +72% YoY (skewed by outliers like Energy Vault +341%, ProKidney +1,075%, TSS +66%), but offset by widespread margin compression (e.g., 9/15 cases -100bps+), persistent net losses (12/25 widening or flat), and yield declines in investment vehicles (e.g., Unknown #1 9.9% from 11.2%, PGIM 9.88% from 11.11%). Retailers like Home Depot (+3.2% sales) and Best Buy (+0.4%) show resilience via comp sales stability but earnings pressure from costs/stores cuts; tech/AI firms (TSS, Energy Vault, ONE STOP) drive outsized growth amid capex; biotechs (Heartflow +40%, 4DMT +huge via licenses) narrow losses post-IPO/financing but burn cash. Capital allocation leans to financings/debt (e.g., Bob's $337M new LT debt, Accelerant $1.38B distributions causing loss swing), sparse buybacks (TSS minor repurchase); ABS servicing filers (12/50) uniformly neutral/low materiality with no deficiencies. Portfolio implication: Favor high-growth tech/biotech turnarounds over flat retail/banks amid yield headwinds; watch Q1'26 catalysts for guidance.

50 high priority50 total filings